参考文献/References:
[1] Clowes JA,Hannon RA,Yap TS,et al.Effect of feeding on bone turnover markers and its impact on biological variability of measurements[J]. Bone,2002,30(6):886-890. DOI: 10.1016/S8756-3282(02)00728-7.
[2] Mabilleau G, Mieczkowska A, Chappard D.Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials[J]. Diabetes, 2014,6(3):260-266. DOI: 10.1111/1753-0407.12102.
[3] Su B, Sheng H, Zhang M,et al.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials[J]. Endocrine, 2015,48(1):107-115. DOI: 10.1007/s12020-014-0361-4.
[4] Irwin N, Flatt PR.New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders[J]. World J Diabetes, 2015,6(15):1285-1295. DOI: 10.4239/wjd.v6.i15.1285.
[5] Bjerre Knudsen L, Madsen LW, Andersen S,et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin relerse and C-cell proliferation[J].Endocrinology,2010,151(4):1473-1486. DOI: 10.1210/en.2009-1272.
[6] Nuche-Berenguer B, Moreno P, Portal-Nun＾ez S, et al. Exendin-4 exerts osteogenic action in insulin-resistant and type 2diabetic states[J]. Regul Pept, 2010, 159(1-3):61-66. DOI: 10.1016/j.regpep.2009.06.010.
[7] Yamada C, Yamada Y, Tsukiyamak K, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption[J].Endocrinology, 2008,149(2):574-579. DOI: 10.1210/en.2007-1292.
[8] Nuche-Berenguer B,Lozano D,Gutiérrez-Rojas I,et a1. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia[J].J Endocrinol,2011,209(2):203-210.DOI: 10.1530/JOE-11-0015.
[9] Ma X, Meng J, Jia M,et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats[J]. J Bone Miner Res, 2013,28(7):1641-1652. DOI: 10.1002/jbmr.1898.
[10] Jeon YK, Bae MJ, Kim JI,et al. Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells[J]. Endocrinol Metab(Seoul),2014,29(4):567-573. DOI: 10.3803/EnM.2014.29.4.567.
[11] Drucker DJ, Yusta B.Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2[J]. Annu Rev Physiol, 2014,76: 561-583. DOI: 10.1146/annurev-physiol-021113-170317.
[12] Lopes LS, Schwartz RP, Ferraz-de-Souza B. et al. The role of enteric hormone GLP-2 in the response of bone markers to a mixed meal in postmenopausal women with type 2 diabetes mellitus[J]. Diabetol Metab Syndr, 2015,7:13.DOI:10.1186/s13098-015-0006-7.
[13] Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD[J]. Bone.2009; 45(5):833-842.DOI: 10.1016/j.bone.2009.07.008.
[14] Walsh JS, Henriksen DB. Feeding and bone[J]. Arch Biochem Biophys, 2010,503(1):11-19. DOI: 10.1016/j.abb.2010.06.020.
[15] Holst JJ, Hartmann B, Gottschalck IB,et al. Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate[J]. Scand J Gastroenterol, 2007,42(7):814-820. DOI: 10.1080/00365520601137272.
[16] Askov-Hansen C, Jeppesen PB, Lund P. et al. Effect of glucagon-like peptide-2 exposure on bone resorption: effectiveness of high concentration versus prolonged exposure[J]. Regul Pept, 2013, 181:4-8. DOI: 10.1016/j.regpep.2012.11.002.
[17] Mieczkowska A, Irwin N, Flatt PR, et al. Glucose-dependent insulinotropic polypeptide(GIP)receptor deletion leads to reduced bone strength and quality[J]. Bone,2013,56(2):337-342. DOI: 10.1016/j.bone.2013.07.003.
[18] Torekov SS, Harsløf T, Rejnmark L,et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor(GIPR)gene is associated with lower bone mineral density and increased fracture risk[J]. J Clin Endocrinol Metab, 2014,99(4):E729-E733. DOI: 10.1210/jc.2013-3766.
[19] Mabilleau G, Mieczkowska A, Irwin N,et al. Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties[J].Bone,2014,63:61-68.DOI: 10.1016/j.bone.2014.02.013.
[20] Kanazawa I. Updates on Lifestyle-Related Diseases and Bone Metabolism. The relationship between incretin and bone metabolism[J].Clin Calcium,2014,24(11):1671-1677.DOI: CliCa141116711677.
[21] Mieczkowska A, Bouvard B, Chappard D,et al. Glucose-dependent insulinotropic polypeptide(GIP)directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures[J]. Bone,2015,74:29-36. DOI: 10.1016/j.bone.2015.01.003.
[22] Mabilleau G, Mieczkowska A, Irwin N,et al. Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties[J].Bone,2014,63:61-68.DOI: 10.1016/j.bone.2014.02.013.
相似文献/References:
[1]姜艳,孟迅吾.雷尼酸锶防治骨质疏松的机制和临床研究[J].国际内分泌代谢杂志,2007,(04):247.
[2]郭丽婷,郝帅,高志红.2型糖尿病患者骨代谢生化指标和钙调激素
与骨密度关系的研究[J].国际内分泌代谢杂志,2015,(02):88.[doi:10.3760/cma.j.issn.1673-4157.2015.02.005]
Guo Liting,Hao Shuai,Gao Zhihong..Research on the relationship between bone mineral density and biochemical index of bone metabolism ,calmodulin hormone in type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(05):88.[doi:10.3760/cma.j.issn.1673-4157.2015.02.005]
[3]尹飞,李菲,李志红.亚临床甲状腺功能异常与骨质疏松[J].国际内分泌代谢杂志,2015,(04):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
Yin Fei,Li Fei,Li Zhihong..Subclinical thyroid dysfunction and osteoporosis[J].International Journal of Endocrinology and Metabolism,2015,(05):258.[doi:10.3760/cma.j.issn.1673-4157.2015.04.012]
[4]王涛,马信龙.骨质疏松发病机制研究进展[J].国际内分泌代谢杂志,2014,(02):99.[doi:10.3760/cma.j.issn.1673-4157.2014.02.008]
Wang Tao,Ma Xinlong..Research progress on pathogenesis of osteoporosis[J].International Journal of Endocrinology and Metabolism,2014,(05):99.[doi:10.3760/cma.j.issn.1673-4157.2014.02.008]
[5]蒋真斌,孙嘉.白细胞介素-17与骨质疏松[J].国际内分泌代谢杂志,2014,(02):103.[doi:10.3760/cma.j.issn.1673-4157.2014.02.009]
Jiang Zhenbin*,Sun Jia.Interleukin-17 and osteoporosis[J].International Journal of Endocrinology and Metabolism,2014,(05):103.[doi:10.3760/cma.j.issn.1673-4157.2014.02.009]
[6]刘海逸,张欣荣,岳晓丹,等.黄连解毒汤对糖耐量减低大鼠的糖尿病
延缓作用[J].国际内分泌代谢杂志,2017,37(03):149.[doi:10.3760/cma.j.issn.1673-4157.2017.03.002]
Liu Haiyi*,Zhang Xinrong,Yue Xiaodan,et al.Effects of huang-lian-jie-du-decoction in delaying diabetes in rats with impaired glucose tolerance[J].International Journal of Endocrinology and Metabolism,2017,37(05):149.[doi:10.3760/cma.j.issn.1673-4157.2017.03.002]
[7]叶勇健 潘天荣.GLP-1受体激动剂在肥胖相关性肾病中的作用机制[J].国际内分泌代谢杂志,2019,39(01):45.[doi:10.3760/cma.j.issn.1673-4157.2019.01.011]
Ye Yongjian,Pan Tianrong.Mechanisms of GLP-1 receptor agonist in obesity-related glomerulopathy[J].International Journal of Endocrinology and Metabolism,2019,39(05):45.[doi:10.3760/cma.j.issn.1673-4157.2019.01.011]
[8]杨梦萦 袁莉.胰岛内源性胰高血糖素样肽-1信号的研究进展[J].国际内分泌代谢杂志,2019,39(06):413.[doi:10.3760/cma.j.issn.1673-4157.2019.06.013]
Yang Mengying,Yuan Li.Recent progress of the islet endogenous glucagon-like peptide-1 signaling[J].International Journal of Endocrinology and Metabolism,2019,39(05):413.[doi:10.3760/cma.j.issn.1673-4157.2019.06.013]
[9]李钰 孟怡媚 刘宽芝.胰高血糖素样肽-1类似物改善肌肉萎缩的研究进展[J].国际内分泌代谢杂志,2022,42(01):41.[doi:10.3760/cma.j.cn121383-20201026-10032]
Li Yu,Meng Yimei,Liu Kuanzhi..Research progress of glucagon-like peptide-1 analogues in ameliorating muscular atrophy[J].International Journal of Endocrinology and Metabolism,2022,42(05):41.[doi:10.3760/cma.j.cn121383-20201026-10032]